Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
OGN.US
id: 1609

Organon ($OGN) Hidden Dividend Cut and Debt Prioritization Case

Investors can submit applications for the lead plaintiff role.
D. New Jersey
Court
2:25-cv-05322
Case number
10/31/2024
Class period Start
04/30/2025
Class period End
07/22/2025
Lead Plaintiff motion deadline
  • $OGN investors filed a claim against Organon for misleading statements about its dividend policy and failing to disclose plans to prioritize debt reduction.
  • After slashing its quarterly dividend by 70% on May 1, 2025, $OGN dropped over 27% .
  • $OGN investors can join this case to be notified about potential recovery.
Case Details:

Between October 31, 2024 and April 30, 2025, Organon repeatedly told investors that maintaining its quarterly dividend was its #1 capital allocation priority. Executives publicly committed to sustaining regular dividend payouts, even after acquiring Dermavant for $500 million in late 2024. CEO Kevin Ali and CFO Matthew Walsh both reassured shareholders that cash flows remained strong and that free cash generation would continue to support dividend payments.

However, Organon failed to disclose that internally, the company had already shifted its focus toward debt reduction due to rising leverage from the Dermavant deal. While publicly highlighting growth drivers like VTAMA and Nexplanon, the company withheld the fact that it was preparing a massive cut to its dividend.

On May 1, 2025, Organon announced it was cutting its dividend from $0.28 to $0.08 per share—a 70% reduction—in order to accelerate debt paydown. Executives admitted they were redirecting nearly $200 million in capital from shareholders to creditors and deprioritizing shareholder returns.

$OGN dropped 27% that day.

Based on these events, $OGN investors filed a claim against Organon and its executives, accusing the company of the following:
  • It misled investors by repeatedly stating the dividend was a top priority while planning to cut it behind the scenes.
  • It failed to disclose a strategic shift to deleveraging, misleading the market on capital allocation plans.
Considering all the representations, investors believe Organon hid key financial risks and withheld critical information to support its stock price ahead of the cut.
Case Type
US Securities Class Action
Case Status
Lead Plaintiff Submission
Alleged Offence
Misleading Statements
Financial Misrepresentation
Fraud
Failure to Disclose
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
05/01/2025
Filing date
05/23/2025
Lead Plaintiff Deadline
07/22/2025

Organon & Co

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Mid...

    Ticker
    OGN.US
    ISIN
    US68622V1061
    CIK
    0001821825
    Sector
    Healthcare
    Industry
    Drug Manufacturers - General
    Country
    USA
    Address
    30 Hudson Street, Jersey City, NJ, United States, 07302